These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3761547)

  • 81. [Laboratory and clinical studies of cefmenoxime in pediatric infections].
    Miyachi Y; Nakashima T; Aso K; Nishikawa K; Ogawa A; Yafuso M; Kuno K
    Jpn J Antibiot; 1982 Oct; 35(10):2459-67. PubMed ID: 6306297
    [TBL] [Abstract][Full Text] [Related]  

  • 82. [Fundamental and clinical studies of cefotiam in neonates and premature infants].
    Motohiro T; Aramaki M; Kawakami A; Tanaka K; Koga T; Shimada Y; Tomita S; Sakata Y; Fujimoto T; Kuda N
    Jpn J Antibiot; 1986 Sep; 39(9):2466-82. PubMed ID: 3467088
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Effect of the administration of cefixime on aerobic fecal flora in children].
    Borderon JC; Bremond M; Laugier J; Despert F
    Pathol Biol (Paris); 1992 May; 40(5):440-2. PubMed ID: 1495826
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Safety and efficacy of cefixime in treatment of respiratory tract infections in Germany.
    Hausen T; Weidlich G; Schmitt J
    Infection; 1995; 23 Suppl 2():S65-9. PubMed ID: 8537134
    [TBL] [Abstract][Full Text] [Related]  

  • 85. [Clinical studies on cefotiam in pediatric infections (author's transl)].
    Okamoto K; Shino K; Fuke H; Watanabe K; Ozaki H
    Jpn J Antibiot; 1981 Jun; 34(6):1019-26. PubMed ID: 6270418
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A review of the safety profile of cefixime.
    Wu DH
    Clin Ther; 1993; 15(6):1108-19. PubMed ID: 8111808
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Clinical role of Cefixime in community-acquired infections.
    Dreshaj Sh; Doda-Ejupi T; Tolaj IQ; Mustafa A; Kabashi S; Shala N; Geca Nj; Aliu A; Daka A; Basha N
    Prilozi; 2011; 32(2):143-55. PubMed ID: 22286619
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [Fundamental and clinical evaluation of ceftriaxone in the pediatric field].
    Sunakawa K; Saitoh N; Adachibara A; Ishizuka Y; Iwata S; Satoh Y; Akita H
    Jpn J Antibiot; 1984 Nov; 37(11):2102-10. PubMed ID: 6098704
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Pharmacokinetics of cefixime in children with urinary tract infections after a single oral dose.
    Mamzoridi K; Kasteridou N; Peonides A; Niopas I
    Pharmacol Toxicol; 1996 Jun; 78(6):417-20. PubMed ID: 8829204
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Studies on the intravenous administration of cefmenoxime in pediatric field].
    Nakazawa S; Sato H; Niino K; Hirama Y; Narita A; Nakazawa S; Chikaoka H; Oka S
    Jpn J Antibiot; 1982 Oct; 35(10):2393-404. PubMed ID: 6306291
    [No Abstract]   [Full Text] [Related]  

  • 91. [Clinical studies of S-1108 fine granules in pediatrics].
    Morita H; Morisawa Y; Hamada F; Kurashige T
    Jpn J Antibiot; 1993 Dec; 46(12):1107-13. PubMed ID: 8107275
    [TBL] [Abstract][Full Text] [Related]  

  • 92. [Fundamental and clinical studies on cefmenoxime in the field of pediatrics].
    Toyonaga Y; Sugita M; Kawamura G; Kurosu Y; Horiuchi K; Hori M; Kohno S; Tatsusawa O; Takahashi T
    Jpn J Antibiot; 1982 Oct; 35(10):2423-39. PubMed ID: 6306294
    [No Abstract]   [Full Text] [Related]  

  • 93. [A parallel comparative double blind study of cefixime with cefroxadine in the treatment of acute lacunar tonsillitis].
    Matsunaga T; Ogino H; Asai H; Shiraishi T; Kawamura S; Onishi S; Ueda R; Kobayashi K; Itoh Y; Sakamoto Y
    Jpn J Antibiot; 1987 Jan; 40(1):25-54. PubMed ID: 3295323
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The pharmacokinetic and bactericidal characteristics of oral cefixime.
    Brittain DC; Scully BE; Hirose T; Neu HC
    Clin Pharmacol Ther; 1985 Nov; 38(5):590-4. PubMed ID: 4053491
    [TBL] [Abstract][Full Text] [Related]  

  • 95. [Effect of cefotaxime in the treatment of infections associated with hematologic diseases].
    Kaneko H; Masaki T; Yamaguchi R; Takahashi N; Umeda M; Shirai T
    Jpn J Antibiot; 1983 Sep; 36(9):2502-14. PubMed ID: 6317914
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Pharmacokinetic profile of cefixime in man.
    Faulkner RD; Yacobi A; Barone JS; Kaplan SA; Silber BM
    Pediatr Infect Dis J; 1987 Oct; 6(10):963-70. PubMed ID: 3696837
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Phase I study of cefixime, a new oral cephalosporin.
    Nakashima M; Uematsu T; Takiguchi Y; Kanamaru M
    J Clin Pharmacol; 1987; 27(5):425-31. PubMed ID: 3693588
    [TBL] [Abstract][Full Text] [Related]  

  • 98. [Clinical studies of S-1108, a new oral cephem, in pediatric patients].
    Yokoo T; Hayashi K; Tsuji Y; Tomimasu K; Kido T; Uehara Y; Mori J; Mori G; Uchida T; Ootsuka Y
    Jpn J Antibiot; 1993 Dec; 46(12):1114-21. PubMed ID: 8107276
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Absolute bioavailability of cefixime in man.
    Faulkner RD; Fernandez P; Lawrence G; Sia LL; Falkowski AJ; Weiss AI; Yacobi A; Silber BM
    J Clin Pharmacol; 1988 Aug; 28(8):700-6. PubMed ID: 3216036
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Cefotaxime therapy of lower respiratory tract infections in intensive-care patients.
    Rondanelli R; Dionigi RV; Calvi M; Dell'Antonio M; Corsico G; Mapelli A
    Int J Clin Pharmacol Res; 1987; 7(1):73-6. PubMed ID: 3583490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.